Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts?
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
If you are wondering whether Pulse Biosciences at around US$18.73 still lines up with its fundamentals, you are not alone. This article will walk through what that price might really represent for you as a shareholder or potential investor.
The stock has been volatile recently, with a 12.6% decline over the last 7 days, a 35.4% return over the last 30 days, a 39.9% return year to date, a 2.3% return over the last year, a very large 3 year return, and a 27.1% decline over 5 years.
These moves are playing out against a backdrop of ongoing interest in Pulse Biosciences and its position in the healthcare space, with investors watching how its technology and pipeline progress translate into market expectations over time. While short term price swings can grab attention, the bigger question is how current news and sentiment line up with what the company might be worth on a fundamental basis.
On our valuation checks, Pulse Biosciences currently holds a 0 out of 6 valuation score. In the sections that follow we will walk through the usual valuation methods and then finish with a different way of thinking about valuation that can help you put all of those models in context.
Pulse Biosciences scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
A DCF model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today in dollar terms.
For Pulse Biosciences, the latest twelve month free cash flow is a loss of $54.683 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, with analyst inputs out to 2030 and then extrapolated figures beyond that. The projections remain in negative territory through 2029, with free cash flow of $68 million, $75 million, $77 million and $43 million, before turning positive to $10 million in 2030. Further estimated free cash flows for 2031 to 2035 range from about $14.0 million to $28.8 million.
When all of these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $2.61 per share. Compared with the recent share price around $18.73, this implies the stock is significantly above the DCF estimate, with the model indicating it is 617.4% overvalued.
For companies that are not yet profitable, price-based metrics like P/E and P/S can be less informative, so P/B often becomes the cleaner reference point because it compares the share price with the accounting value of net assets.
In general, a higher multiple can reflect stronger growth expectations or lower perceived risk, while a lower multiple can reflect lower growth expectations or higher risk. There is no single “right” number; however, it helps to compare a stock’s P/B with reasonable benchmarks.
Pulse Biosciences currently trades on a P/B ratio of 15.79x. That is well above the Medical Equipment industry average of about 2.55x and the peer average of about 2.93x. Simply Wall St also uses a proprietary “Fair Ratio” for each company, which is the preferred multiple it would expect given factors like earnings growth, profit margin, industry, market cap and specific risks.
This Fair Ratio framework is often more useful than just lining the company up against peers because it adjusts for company-specific characteristics rather than assuming all companies in the same industry deserve similar multiples.
With the Fair Ratio not available here, the high gap between Pulse Biosciences current P/B and sector benchmarks points to the shares trading at an expensive level on this measure.
Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Pulse Biosciences business, such as whether you lean toward a higher fair value of US$30 or a lower one of US$22, to your own revenue, earnings and margin assumptions. This turns those assumptions into a fair value you can constantly compare with the live share price, helping you decide if the stock appears attractive or stretched. All of this is available within an easy Community tool that updates automatically as fresh news or earnings arrive, so your buy and sell thinking stays aligned with your evolving thesis rather than a static model.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
